Bachem Holding Valuation
Is BANBZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BANBZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BANBZ (CHF68.55) is trading above our estimate of fair value (CHF24.63)
Significantly Below Fair Value: BANBZ is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BANBZ?
Key metric: As BANBZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
What is BANBZ's PE Ratio? | |
---|---|
PE Ratio | 45.2x |
Earnings | CHF 113.57m |
Market Cap | CHF 5.14b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 8.6x |
Enterprise Value/EBITDA | 29.9x |
PEG Ratio | 2.5x |
Price to Earnings Ratio vs Peers
How does BANBZ's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 53.7x | ||
ERGO Ergomed | 46.7x | 14.2% | UK£701.1m |
HVO hVIVO | 9.9x | -15.2% | UK£172.8m |
HIK Hikma Pharmaceuticals | 17.8x | 11.2% | UK£4.0b |
GNS Genus | 140.2x | 37.0% | UK£1.1b |
BANBZ Bachem Holding | 45.2x | 17.9% | CHF 5.1b |
Price-To-Earnings vs Peers: BANBZ is good value based on its Price-To-Earnings Ratio (45.2x) compared to the peer average (56x).
Price to Earnings Ratio vs Industry
How does BANBZ's PE Ratio compare vs other companies in the European Life Sciences Industry?
1 Company | Price / Earnings | Estimated Growth | Market Cap |
---|---|---|---|
1 Company | Estimated Growth | Market Cap | |
---|---|---|---|
Price-To-Earnings vs Industry: BANBZ is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the European Life Sciences industry average (37.1x).
Price to Earnings Ratio vs Fair Ratio
What is BANBZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 45.2x |
Fair PE Ratio | 26.9x |
Price-To-Earnings vs Fair Ratio: BANBZ is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the estimated Fair Price-To-Earnings Ratio (26.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 68.55 | CHF 85.00 +24.0% | 12.2% | CHF 100.00 | CHF 71.00 | n/a | 7 |
Nov ’25 | CHF 70.05 | CHF 84.83 +21.1% | 13.2% | CHF 100.00 | CHF 71.00 | n/a | 6 |
Oct ’25 | CHF 70.00 | CHF 82.83 +18.3% | 16.0% | CHF 100.00 | CHF 65.00 | n/a | 6 |
Sep ’25 | CHF 81.55 | CHF 82.83 +1.6% | 16.0% | CHF 100.00 | CHF 65.00 | n/a | 6 |
Aug ’25 | CHF 79.28 | CHF 77.14 -2.7% | 22.9% | CHF 100.00 | CHF 52.00 | n/a | 7 |
Jul ’25 | CHF 83.48 | CHF 75.67 -9.4% | 22.1% | CHF 100.00 | CHF 52.00 | n/a | 6 |
Jun ’25 | CHF 80.05 | CHF 70.80 -11.6% | 19.6% | CHF 85.00 | CHF 52.00 | n/a | 5 |
May ’25 | CHF 80.50 | CHF 70.80 -12.0% | 19.6% | CHF 85.00 | CHF 52.00 | n/a | 5 |
Apr ’25 | CHF 86.10 | CHF 70.80 -17.8% | 19.6% | CHF 85.00 | CHF 52.00 | n/a | 5 |
Mar ’25 | CHF 70.15 | CHF 71.17 +1.4% | 17.6% | CHF 85.00 | CHF 52.00 | n/a | 6 |
Feb ’25 | CHF 58.03 | CHF 71.17 +22.6% | 17.6% | CHF 85.00 | CHF 52.00 | n/a | 6 |
Jan ’25 | CHF 65.00 | CHF 73.17 +12.6% | 13.7% | CHF 85.00 | CHF 56.00 | n/a | 6 |
Dec ’24 | CHF 64.95 | CHF 75.33 +16.0% | 9.3% | CHF 85.00 | CHF 64.00 | n/a | 6 |
Nov ’24 | CHF 66.05 | CHF 75.33 +14.1% | 9.3% | CHF 85.00 | CHF 64.00 | CHF 70.05 | 6 |
Oct ’24 | CHF 67.65 | CHF 77.00 +13.8% | 12.7% | CHF 95.00 | CHF 64.00 | CHF 70.00 | 6 |
Sep ’24 | CHF 82.20 | CHF 80.00 -2.7% | 14.1% | CHF 97.00 | CHF 65.00 | CHF 81.55 | 7 |
Aug ’24 | CHF 80.10 | CHF 82.83 +3.4% | 13.6% | CHF 97.00 | CHF 65.00 | CHF 79.28 | 6 |
Jul ’24 | CHF 77.75 | CHF 87.60 +12.7% | 9.3% | CHF 97.00 | CHF 74.00 | CHF 83.48 | 5 |
Jun ’24 | CHF 93.55 | CHF 91.75 -1.9% | 4.8% | CHF 97.00 | CHF 86.00 | CHF 80.05 | 4 |
May ’24 | CHF 96.90 | CHF 88.20 -9.0% | 11.2% | CHF 100.00 | CHF 71.00 | CHF 80.50 | 5 |
Apr ’24 | CHF 91.95 | CHF 88.20 -4.1% | 11.2% | CHF 100.00 | CHF 71.00 | CHF 86.10 | 5 |
Mar ’24 | CHF 94.00 | CHF 88.20 -6.2% | 11.2% | CHF 100.00 | CHF 71.00 | CHF 70.15 | 5 |
Feb ’24 | CHF 80.70 | CHF 86.80 +7.6% | 11.7% | CHF 100.00 | CHF 71.00 | CHF 58.03 | 5 |
Jan ’24 | CHF 80.45 | CHF 86.80 +7.9% | 11.7% | CHF 100.00 | CHF 71.00 | CHF 65.00 | 5 |
Dec ’23 | CHF 90.20 | CHF 74.40 -17.5% | 23.4% | CHF 95.00 | CHF 48.00 | CHF 64.95 | 5 |
Nov ’23 | CHF 69.15 | CHF 72.83 +5.3% | 21.0% | CHF 95.00 | CHF 48.00 | CHF 66.05 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
hVIVO
UK£172.8m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.25
7D
-10.9%
1Y
39.6%
Dermapharm Holding
€1.9b
Manufactures and sells off-patent branded pharmaceutical products in Germany.
0A5J
€34.35
7D
7.7%
1Y
-14.5%
Regeneron Pharmaceuticals
US$82.0b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$760.78
7D
-7.0%
1Y
-4.4%